The prescription opioid epidemic in a nutshell

This forum made possible through the generous support of SDN members, donors, and sponsors. Thank you.
how many of you have patients who are
1) Under age 65
2) No terminal cancer or cancer in remission
3) minimal pathology
4) on high dose opioids
5) functioning at a high level (ie: working).

Honestly, quite a few. These are legacy patients that i inherited. Each one of them hears about the benefits of cessation of opioid therapy each appointment, and are told that opioid therapy will be stopped if they go on disability for the pain syndrome.

I am actively tapering 2 patients right now, and rotated one patient off of her high dose opioid last month...

Members don't see this ad.
 
Honestly, quite a few. These are legacy patients that i inherited. Each one of them hears about the benefits of cessation of opioid therapy each appointment, and are told that opioid therapy will be stopped if they go on disability for the pain syndrome.

I am actively tapering 2 patients right now, and rotated one patient off of her high dose opioid last month...

This is not your fault. But, what you are doing with these folks is actually opioid maintenance therapy, not pain management. These are the lost generation.
 
Honestly, quite a few. These are legacy patients that i inherited....

Why?
This does not mean you have to continue something that you obviously feel is inappropriate,
refer to addiction specialists or wean them off over the next couple months..if they get outside meds stop rxing immediately
 
Members don't see this ad :)
Why?
This does not mean you have to continue something that you obviously feel is inappropriate,
refer to addiction specialists or wean them off over the next couple months..if they get outside meds stop rxing immediately

How successful are you at tapering and discontinuing opioids among the opioid tolerant. Do they find other prescribers? Do they call your office a lot? etc?
 
Why?
This does not mean you have to continue something that you obviously feel is inappropriate,
refer to addiction specialists or wean them off over the next couple months..if they get outside meds stop rxing immediately

its a balance between what i feel may be inappropriate vs. what is in the patient's best interest.

those patients whose dose i feel is inappropriate (usually over 200 MED), i have always stopped writing and given them resources as to addiction specialists and withdrawal symptoms.

however, someone with a marginal symptomatology on a high dose (up to 200 MED), but has excellent ODI, has remained functional by working 40+ hours a week, has had no signs of inappropriate use, UDS always appropriate, has followed all recommendations towards improving their pain management, ...

i feel that it is ethically wrong to withhold opioids in those individuals.
 
How successful are you at tapering and discontinuing opioids among the opioid tolerant. Do they find other prescribers? Do they call your office a lot? etc?

Very successful.

Of the voluntary patients, my N is roughly 40... only one still is jonesing for going back on. I tell them that it is going to be very painful. they get tapered over a 2 month or so period of time. they get at least 1 followup appointment 3-4 weeks into the taper, sometimes up to every other week.

The purpose of the taper is to give them back their quality of life. they all buy into the process before we get started, esp. family. they all have come to the conclusion that the meds dont help, and their lives are miserable because of them. Once we start, we dont go back (well, i did on one.. metastic lung cancer trumps almost all).

its a hell of a lot more work than keeping them on the scripts - i probably spend what, 5 hours in appt time over 3-4 months to do this. All of them get referred to pain psych during the process too, to help. i cannot recall any of these people transferring to other pain providers or leaving the clinic.
 
Very successful.

Of the voluntary patients, my N is roughly 40... only one still is jonesing for going back on. I tell them that it is going to be very painful. they get tapered over a 2 month or so period of time. they get at least 1 followup appointment 3-4 weeks into the taper, sometimes up to every other week.

The purpose of the taper is to give them back their quality of life. they all buy into the process before we get started, esp. family. they all have come to the conclusion that the meds dont help, and their lives are miserable because of them. Once we start, we dont go back (well, i did on one.. metastic lung cancer trumps almost all).

its a hell of a lot more work than keeping them on the scripts - i probably spend what, 5 hours in appt time over 3-4 months to do this. All of them get referred to pain psych during the process too, to help. i cannot recall any of these people transferring to other pain providers or leaving the clinic.

The addiction literature says abstinence alone works 10 to 30% of the time. Moreover, there is no published data to suggest that there is a measurable difference between what we would call 'opioid tolerant' vs 'addicted'. The treatment for both is the same. Ergo, if you do this long enough - without committing suicide - your data will look like the addictionology data: 10 - 30% success.

It's the rare CNP patient on >100MED that succeeds on a wean.
 
its a balance between what i feel may be inappropriate vs. what is in the patient's best interest.

those patients whose dose i feel is inappropriate (usually over 200 MED), i have always stopped writing and given them resources as to addiction specialists and withdrawal symptoms.

however, someone with a marginal symptomatology on a high dose (up to 200 MED), but has excellent ODI, has remained functional by working 40+ hours a week, has had no signs of inappropriate use, UDS always appropriate, has followed all recommendations towards improving their pain management, ...

i feel that it is ethically wrong to withhold opioids in those individuals.

In my practice , I personally feel it is ethically wrong to give patients with marginal symptoms long term opioids , I don't care if they are gainfully employed. Don't see how perpetuating long term narcotics is in the patient's "best interest"
 
How successful are you at tapering and discontinuing opioids among the opioid tolerant. Do they find other prescribers? Do they call your office a lot? etc?

First of all I don't continue prescribing narcotics on "inherited patients" or persons whose provider left the community if I feel they are not appropriate.
Many never return which is fine. The few I taper rate their pain the same after gettings off the narcs as before.
 
The opioid maintained functionality of patients is easy to test: gradual withdrawal from opioids with serial RM and Oswestry testing, VAS assessment, until the patient is off opioids for 3 months. Then retest RM and Oswestry, and VAS. If these are much much worse, then it is likely the patient was actually benefitting from opioids.
 
The addiction literature says abstinence alone works 10 to 30% of the time. Moreover, there is no published data to suggest that there is a measurable difference between what we would call 'opioid tolerant' vs 'addicted'. The treatment for both is the same. Ergo, if you do this long enough - without committing suicide - your data will look like the addictionology data: 10 - 30% success.

It's the rare CNP patient on >100 MED that succeeds on a wean.

My experience is that "not starting" and "taking them off" are very, very different clinical endeavors. The latter can be very exhausting and frought with hazards without the right resources.
 
My experience is that "not starting" and "taking them off" are very, very different clinical endeavors. The latter can be very exhausting and frought with hazards without the right resources.

My experience is when a patient is told a taper is in order they either, A-take the first taper script and start looking for a new doctor (most), B-aren't motivated but make an attempt, fail, then move to A (a few), or C-are very self motivated to do so and succeed (a few less, but not zero.)

Usually, "C" are those that come up with the idea themselves, ie, "I'm a slave to this stuff, it's not helping my pain, and it's not making me feel good. How do I get off this stuff?" These do well, and seem to swear off opiates in the future. They'll usually say, "I didn't even ask to be on the stuff, but my doc kept suggesting we up the dose every time I went in. I thought he knew what he was doing". I would put such patients in the category of "physically dependent and physically tolerant but not 'addicted'".

As far as the others (A & B), I think it helps to let them know you aren't playing co-dependent. That may inch them closer to having a "category C" awakening. Continuing to add more of a therapy that's not working, does no one any favors.
 
Last edited:
In my practice , I personally feel it is ethically wrong to give patients with marginal symptoms long term opioids , I don't care if they are gainfully employed. Don't see how perpetuating long term narcotics is in the patient's "best interest"

i would disagree. in this select group of Legacy patients (remember that i took over a clinic of a couple of thousand patients), i think it is ethically wrong to immediately and unilaterally decide to stop medications without consideration of the individual patient.

in their case, we are not purely treating a number, or a "condition". we are treating a patient on therapy for years, and in their case, they have shown that they 1. are tolerating the medication 2. are benefitting from the medication 3. have good continued functionality on the medication. Harm reduction in stopping meds may not provide that.

new patients with marginal symptoms are never exposed to this issue, as they are not provided opioids. "new to me" patients who have been given opioids from other providers are not given them - theres probably a reason that the original doc isnt prescribing.



emd is correct that, without a patient's understanding and willingness to participate, the vast majority of patients will seek alternate care, most commonly from the PCP. It is one great way of losing a potential referral base, by alienating a PCP and essentially "forcing" them to confront and, most commonly, take over the opioid prescriptions. The patient doesnt benefit, and now noone is really monitoring for side effects, compliance, etc.
 
Members don't see this ad :)
The opioid maintained functionality of opioid addicts is easy to test: gradual withdrawal from opioids with serial RM and Oswestry testing, VAS assessment, until the addict is off opioids for 3 months. Then retest RM and Oswestry, and VAS. If these are much much worse, then it is likely the addict was actually benefitting from their maintanence therapy.
 
  • Like
Reactions: 1 user
In my practice , I personally feel it is ethically wrong to give patients with marginal symptoms long term opioids , I don't care if they are gainfully employed. Don't see how perpetuating long term narcotics is in the patient's "best interest"

Preach on my brother!!! It just don't make no sense. Opioids are not always the answer "when nothing else works"
 
Lots of old cars, a few derringers, and some assorted property. I wonder if the DEA sells confiscated property on Ebay?
 
http://www.ncbi.nlm.nih.gov/pubmed/23070654

J Gen Intern Med. 2012 Oct 16. [Epub ahead of print]

Unintentional Prescription Opioid-Related Overdose Deaths: Description of Decedents by Next of Kin or Best Contact, Utah, 2008-2009.

Johnson EM, Lanier WA, Merrill RM, Crook J, Porucznik CA, Rolfs RT, Sauer B.


Source

Utah Department of Health, Prescription Pain Medication Program, Salt Lake City, UT, USA.


Abstract

BACKGROUND:

Little is known about the characteristics that may predispose an individual to being at risk for fatal overdose from prescription opioids.

OBJECTIVE:

To identify characteristics related to unintentional prescription opioid overdose deaths in Utah.

DESIGN:

Interviews were conducted (October 2008-October 2009) with a relative or friend most knowledgeable about the decedent's life.

SUBJECTS:

Analyses involved 254 decedents aged 18 or older, where cause of death included overdose on at least one prescription opioid.

KEY RESULTS:

Decedents were more likely to be middle-aged, Caucasian, non-Hispanic/Latino, less educated, not married, or reside in rural areas than the general adult population in Utah. In the year prior to death, 87.4 % were prescribed prescription pain medication. Reported potential misuse prescription pain medication in the year prior to their death was high (e.g., taken more often than prescribed [52.9 %], obtained from more than one doctor during the previous year [31.6 %], and used for reasons other than treating pain [29.8 %, almost half of which "to get high"]). Compared with the general population, decedents were more likely to experience financial problems, unemployment, physical disability, mental illness (primarily depression), and to smoke cigarettes, drink alcohol, and use illicit drugs. The primary source of prescription pain medication was from a healthcare provider (91.8 %), but other sources (not mutually exclusive) included: for free from a friend or relative (24 %); from someone without their knowledge (18.2 %); purchase from a friend, relative, or acquaintance (16.4 %); and purchase from a dealer (not a pharmacy) (11.6 %).

CONCLUSIONS:

The large majority of decedents were prescribed opioids for management of chronic pain and many exhibited behaviors indicative of prescribed medication misuse. Financial problems, unemployment, physical disability, depression, and substance use (including illegal drugs) were also common.
 
"Coping with founder's syndrome requires discussion of the problem, a plan of action, and interventions by the founder, the board and or by others involved in the organization. The objective of the plan should be to allow the organization to make a successful transition to a mature organizational model without damage to either the organization itself or the individuals concerned."

http://www.youtube.com/watch?v=o9qoP5ecmYc&feature=youtu.be
 
Please PM me who you are referring to. Thx.

FDA: Opioid Labeling Debated at Hearing

By Kristina Fiore, Staff Writer, MedPage Today
Published: February 07, 2013


BETHESDA, Md. -- Advocates and pain management groups aired concerns Thursday over a citizen petition to change opioid labeling during the first of a 2-day FDA hearing here.

Speaking on behalf of the American Pain Society, Edward Michna, MD, an anesthesiologist at Brigham & Women's Hospital in Boston, cited an anecdote in which an insurance company had denied payment of opioid therapy for a patient because the petition noted a lack of evidence for use in chronic pain.

"You can see how insidious this is," Michna said. "Insurance companies will use any evidence they can to deny access to care."

Wendy Foster, an advocate for the U.S. Pain Foundation, called the petition's requests "extreme measures" that would block access for patients in legitimate pain.

The petition, filed last summer by Physicians for Responsible Opioid Prescribing (PROP) and Public Citizen, was signed by nearly 40 doctors, researchers, and public health officials aiming to make it more difficult for drug companies to market opioids for chronic, noncancer pain.

Specifically, it asks FDA to strike the word "moderate" from opioid labels in chronic pain; to include an upper limit (the equivalent of 100 mg of morphine a day) on the daily dose of opioid in this setting; and to limit therapy to 90 days in this group.

Any other uses then would become off-label, preventing companies from promoting the drugs for those uses in advertising, continuing medical education (CME) programs, and in other physician education settings.

FDA held the 2-day hearing largely to discuss the petition and to gather evidence on the safe and effective medical use of opioids, since the petition's impetus was the lack of evidence for use of opioids in chronic, noncancer pain beyond 12 weeks -- the genesis of the 90 days mentioned in the petition.

Directors of various FDA divisions, including anesthesiology, epidemiology, and controlled substances, heard testimony from patients, clinicians, and other entities with interests in opioid drugs.

Andrew Kolodny, MD, chair of psychiatry at Maimonides Medical Center in Brooklyn and co-founder of PROP, said interest groups have misinterpreted the petition as asking FDA to impose prescribing limits.

"That's not our intention," Kolodny said during the hearing. "We're asking for a more narrow indication and more specific instructions on labels such that use beyond the suggested parameters would become off-label."

He noted that off-label use is appropriate and legal, and at times can be the standard of care. It simply brings to the clinician's attention the fact that there is a dearth of evidence for the long-term use of opioids in chronic pain, he said.

But Bob Twillman, director of policy and advocacy for the American Academy of Pain Management, charged that the "absence of evidence is not evidence of absence."

Twillman also cited the challenges of distinguishing cancer pain from noncancer pain, as complications of cancer treatment that linger long after the disease is gone would fall into a gray area -- a point cited by other groups that spoke out against the petition, including the American Association of Hospice and Palliative Medicine.

A recurring theme in recent FDA hearings on issues related to opioid prescribing has been striking a balance between access for patients in legitimate pain, and abuse and diversion. Again, patient advocates on both sides of the issue turned out, seemingly pitting families who lost loved ones to addiction against pain patients who feared losing access to their medications.

Gwenn Herman, a social worker with chronic pain and founder of the pain advocacy group Pain Connection, turned away from the panel during her presentation and addressed the bereaved families directly. She acknowledged their grief and apologized for their loss, but noted that their concerns are "two separate issues" that shouldn't be at opposition.

Other speakers included representatives from Quest Diagnostics, maker of urine screens for toxicology analysis, and Covectra, which produces electronic technology to track prescriptions. These groups provided alternative approaches to risk management other than changing the label, according to Douglas Throckmorton, MD, deputy director of the FDA's Center for Drug Evaluation and Research (CDER), who conducted the meeting.

Several public health researchers also presented evidence of addiction and overdose death rates that have tracked increases in prescribing of opioids over the last 10 years.

Kolodny referenced a similar panel held by FDA about 10 years ago that asked top experts in pain medicine whether opioid labels should be so broad.

"At that time, the people you asked who were working for industry, who were championing this effort, said yes, they wanted the broad label, and you've listened to them," Kolodny said. "I think we have enough evidence today to suggest a very serious mistake was made, and it's time to fix that mistake."
 
This is comment on Other: Physicians for Responsible Opioid Prescribing - Citizen Petition
Docket ID: FDA-2012-P-0818 RIN:

Topics: No Topics associated with this document
View Document:
More

Document Subtype: Electronic Regulation from Form
Status: Posted
Received Date: January 21 2013, at 12:00 AM Eastern Standard Time
Date Posted: January 22 2013, at 12:00 AM Eastern Standard Time
Comment Start Date: July 30 2012, at 12:00 AM Eastern Daylight Time
Tracking Number: 1jx-838q-54lz
Submission Type: 3
Number of Duplicate Submissions: 1
Country: United States
State or Province: CA
Category: Health Professional - A0007



Comment:
Opioids are an essential drug group within the medical treatment arsenal yet it is indisputable that we have a serious problem of over-reliance on and excessive prescribing of them. Reevaluation of the current labeling for opioids for chronic pain is warranted based on the substantial change in risk data over the past several years and the current state of excessive opioid prescribing. The problem of excessive prescribing points directly to prescribers’ substantial need for better education and guidance. Clear consensus on safe parameters for opioid dosing would benefit prescribers as well as patients.--------------- Both the supporters and opponents of the specific proposed labeling change with whom I have reviewed the subject are in favor of reevaluating the labeling of opioids for chronic pain but most are not as certain about the specific changes that are needed to best solve the problem. Such views on both sides are firmly grounded in finding the right balance for patients dealing with intractable pain. Although I am not an expert in FDA labeling or its effects, I know that every prescriber of opioids must firmly grasp how to use these drugs safely at the initial prescription no matter the dose and recognize that there is no special safe zone in which less knowledge, vigilance or caution is required. --------------- Reducing prescription drug abuse and providing relief for those in chronic pain should not be conflicting or mutually exclusive goals. The specific proposed label changes represent a good starting point for a much needed examination and debate. This discussion about labeling must also become an integral part of prescriber education and advance our commitment to expanded research. I remain hopeful that this process will foster significant positive changes in the way opioids are prescribed for chronic pain in our country. Scott Fishman, MD
 
http://latimesblogs.latimes.com/lanow/2013/02/at-a-federal-hearing.html

Doctor who lost license offers drug advice to FDA

At a hearing this week in Bethesda, Md., on reducing fatal prescription overdoses, a federal panel heard from an East Bay man identified as a “clinician” that the real problem was that some doctors weren’t prescribing enough drugs.

Trouble was, Edward Manougian was not a clinician— not any more.

He lost his California medical license over the very practices on which he lectured the panel of U.S. Food & Drug Administration officials.

The 83-year-old Berkeley man pointed with a yardstick to a hand-drawn diagram sketching his theory on the “pathophysiology of pain.” Some patients require high doses of powerful painkillers known as opioids, he said. He faulted doctors who fail to “treat them correctly”--forcing patients to turn to emergency rooms and the streets for drugs.

Many opioid overdoses, he said, were caused by "patients not getting the right dose and having to get drugs off the street.”

His testimony, submitted via videotape for the hearing that ended Friday, was webcast live by the agency. The FDA does not screen people who request to speak at public hearings and allows them to identify themselves, a spokeswoman said.

Manougian did not say that the Medical Board of California had revoked his license in October after finding that the combinations and doses of drugs he ordered for several patients were dangerous and demonstrated gross negligence.

Two of his patients in their 30s fatally overdosed on painkillers after he gave them prescriptions for the same type of drugs, Medical Board records show.

Manougian asserted in his defense to the state board that he was following his “pathophysiology of pain” theory, the same one that he presented to the FDA. A medical board expert called the theory "supposition" and said that "it does not represent any of the current science or knowledge of chronic pain."

In recommending license revocation, Administrative Law Judge Mary-Margaret Anderson said drugs prescribed by Manougian have ended up on the street.

“With blinders firmly in place," she wrote, "he conducted his practice in accordance with his own idiosyncratic views and methods, in disregard of the safety of his patients and the public health."

In an interview Friday, Manougian maintained that his care was appropriate. He has filed an appeal in an attempt to win his license back.

For now, though, Manougian is barred from practicing medicine or calling himself a doctor in California, said Lynda Gledhill, a spokeswoman for the state attorney general’s office.

In December, two months after he lost his license, Manougian said he registered to testify at the FDA hearing as "a physician, a clinician."

"I'm a doctor, and my license has not really ended yet," he said, because his case is on appeal. "I'm a clinician. I'm just not an active clinician."

Marvin Firestone, a physician and Manougian's lawyer, said he "certainly couldn't put himself out as a physician with an unrestricted license at this time." He added: "Probably the correct thing to say is, 'I have been a clinician for 55 years,' putting it in the past tense."
 
http://latimesblogs.latimes.com/lanow/2013/02/at-a-federal-hearing.html

Doctor who lost license offers drug advice to FDA

At a hearing this week in Bethesda, Md., on reducing fatal prescription overdoses, a federal panel heard from an East Bay man identified as a “clinician” that the real problem was that some doctors weren’t prescribing enough drugs.

Trouble was, Edward Manougian was not a clinician— not any more.

He lost his California medical license over the very practices on which he lectured the panel of U.S. Food & Drug Administration officials.

The 83-year-old Berkeley man pointed with a yardstick to a hand-drawn diagram sketching his theory on the “pathophysiology of pain.” Some patients require high doses of powerful painkillers known as opioids, he said. He faulted doctors who fail to “treat them correctly”--forcing patients to turn to emergency rooms and the streets for drugs.

Many opioid overdoses, he said, were caused by "patients not getting the right dose and having to get drugs off the street.”

His testimony, submitted via videotape for the hearing that ended Friday, was webcast live by the agency. The FDA does not screen people who request to speak at public hearings and allows them to identify themselves, a spokeswoman said.

Manougian did not say that the Medical Board of California had revoked his license in October after finding that the combinations and doses of drugs he ordered for several patients were dangerous and demonstrated gross negligence.

Two of his patients in their 30s fatally overdosed on painkillers after he gave them prescriptions for the same type of drugs, Medical Board records show.

Manougian asserted in his defense to the state board that he was following his “pathophysiology of pain” theory, the same one that he presented to the FDA. A medical board expert called the theory "supposition" and said that "it does not represent any of the current science or knowledge of chronic pain."

In recommending license revocation, Administrative Law Judge Mary-Margaret Anderson said drugs prescribed by Manougian have ended up on the street.

“With blinders firmly in place," she wrote, "he conducted his practice in accordance with his own idiosyncratic views and methods, in disregard of the safety of his patients and the public health."

In an interview Friday, Manougian maintained that his care was appropriate. He has filed an appeal in an attempt to win his license back.

For now, though, Manougian is barred from practicing medicine or calling himself a doctor in California, said Lynda Gledhill, a spokeswoman for the state attorney general’s office.

In December, two months after he lost his license, Manougian said he registered to testify at the FDA hearing as "a physician, a clinician."

"I'm a doctor, and my license has not really ended yet," he said, because his case is on appeal. "I'm a clinician. I'm just not an active clinician."

Marvin Firestone, a physician and Manougian's lawyer, said he "certainly couldn't put himself out as a physician with an unrestricted license at this time." He added: "Probably the correct thing to say is, 'I have been a clinician for 55 years,' putting it in the past tense."

Fine, that guy wins DOTW.
 
In response to the DEA investigation and potential malpractice lawsuits, Webster's attorney asked another Salt Lake City pain specialist, Perry Fine, MD, to review a number of overdose cases from the clinic, Fine said.

what did the pot say to the kettle?

Problem is, Webster is advising Medscape, and the impact of what he is "teaching"....
 
http://m.sltrib.com/sltrib/mobile3/55962410-219/drug-research-industry-trials.html.csp

—

Industry funding research. » In Utah, ProPublica’s data also spotlight a multimillion dollar industry of contract research organizations, or CROs, private companies that drug makers pay to test their drugs.

Among them is CRI LifeTree Research, which has received at least $3.4 million in drug company payments since 2009, according to ProPublica.

Co-founder Lynn Webster, an anesthesiologist, is listed as having received the single largest payment in the state: $1,687,771 from Cephalon, a big maker of pain medications. Only three other doctors in the country received more from Cephalon.

Nationally, Webster is among the top 50 for single largest payments received, behind marquee hospitals, such as the Mayo Clinic, Cleveland Clinic and Duke and Harvard Universities.

A nationally recognized expert in pain management, Webster is under investigation by the U.S. Drug Enforcement Administration, which is looking into opioid overdose deaths of patients of his former pain clinic. A Senate Committee is probing his financial ties to Big Pharma.

Webster no longer sees patients, but serves as a medical director at LifeTree’s South Salt Lake location. Research payments to him cover overhead and other costs, including his salary as a lead researcher, he said.

"Research inevitably leads to better education, better systems and better therapies — things that are indispensable for medical advancement and quality .
 
argh... just went to the propublica website and found my name...

i refuse to have drug companies pay for my meals - so i always order separately and pay separately for my meals at drug events (i primarily go to hang out with other buddy pain docs)... specifically to avoid showing up on any website like probublica

and CEPHALON (of all) shows having paid $113 for a meal for me 2 years ago... they must have included my name for everybody that showed up... pisses me off.
 
I did the same. I am guilty of $250-$1,000 in lunches
with Allergan. My old office partners used to let staff
arrange 1/wk drug lunches. Looks like every BTX lunch
was attributed to moi.
 
STEVEN M LOBEL ATHENS Ga. Forest 2012 Speaking $1,450
STEVEN LOBEL CANTON Ga. Eli Lilly 2011 Meals $504
STEVEN MICHAEL LOBEL CANTON Ga. Allergan 2011 Meals $1-1,000

And a bunch of other stuff for 10-38 bucks.

One dinner and one lunch lecture for Savella.
A year's worth of going to hear a national speaker for Lilly on Cymbalta.
Allergan has Botox? Anything else? Might have gotten a pen in 2011?
 
They gotta add device mgt to this database. Lots more money spent there.
 
Allergen 1-1000

Why do I find this irritating? I generally support transparency. Feels like there is some implied shady quid pro quo for me getting the info I need to bill correctly for a very expensive drug with no mark up and have my staff of 4 get a free sandwich.
 
argh... just went to the propublica website and found my name...

i refuse to have drug companies pay for my meals - so i always order separately and pay separately for my meals at drug events (i primarily go to hang out with other buddy pain docs)... specifically to avoid showing up on any website like probublica

and CEPHALON (of all) shows having paid $113 for a meal for me 2 years ago... they must have included my name for everybody that showed up... pisses me off.

yes.

from the perspective of a drug rep - she told me she has to give the company the name of a doctor that she is presenting to, in order to justify the costs.

she isnt coming back...
 
Dosing guidlines won't work. Guess Lynn & Perry don't consider 10 fewer opioid OD deaths per month a success: http://www.ncbi.nlm.nih.gov/pubmed/22213274

Pain Group Says Simple Dosing Change Won't Fix Prescription Drug Abuse Problem

Changing the label on opioid pain medications to limit their continuous use to 90 days would do little to stop drug abuse while depriving millions of Americans of the medication they need to live a reasonable life, according to a leading professional organization representing pain specialists.


In written comments to the FDA, the American Academy of Pain Medicine (AAPM) renewed its commitment to fighting prescription drug abuse but warned that adopting the proposal could effectively eliminate the use of opioids for chronic noncancer pain, usually defined as pain lasting longer than 90 days.



“This position could potentially leave an untold number of pain sufferers with few treatment options, given the on-label restrictions imposed by many insurers, including Medicare/Medicaid,” AAPM leadership wrote.
In light of the complexities surrounding this and other proposed labeling changes, the FDA held a public hearing in March to consider the science behind the safety and effectiveness of administering opioids for chronic noncancer pain. A decision on labeling has yet to be made.



The Institute of Medicine (IOM) reports that 100 million Americans live with chronic pain. Chronic opioid therapy may not be a first choice for the control of pain but can effective for some patients who don’t respond to other therapies and who would otherwise suffer terribly, according to the AAPM.



Other proposals under consideration by the FDA include limiting long-term opioid therapy to severe pain (excluding moderate pain) and setting a daily dosage limit of 100 mg morphine equivalents. The AAPM stated that there is evidence supporting that patients vary widely in their experience of pain and their response to medications, in part because of genetic differences. The group called the 100-mg limit “unsubstantiated” and expressed fear that a sole focus on dose could lull prescribers into a false sense of security by allowing them to ignore important risk factors.
 
Allergen 1-1000

Why do I find this irritating? I generally support transparency. Feels like there is some implied shady quid pro quo for me getting the info I need to bill correctly for a very expensive drug with no mark up and have my staff of 4 get a free sandwich.

$1-1000 - that's quite a range. Jim gets a Snickers bar with a Celebrex label (yes, Pfizer, I know), and John gets an iPad, and they're both listed together.
 
http://jama.jamanetwork.com/article.aspx?articleID=1686609

Viewpoint |
ONLINE FIRST
Opioid Analgesics—Risky Drugs, Not Risky Patients FREE ONLINE FIRST
Deborah Dowell, MD, MPH; Hillary V. Kunins, MD, MPH, MS; Thomas A. Farley, MD, MPH
[+] Author Affiliations
JAMA. 2013;():1-2. doi:10.1001/jama.2013.5794. Text Size: A A A
Published online May 9, 2013
Article
References
From 1999 to 2010 the number of people in the United States dying annually from opioid analgesic–related overdoses quadrupled, from 4030 to 16 651.1 Patients' predisposition to overdose could not have changed substantially in that time; what has changed substantially is their exposure to opioids. During this same time, the amount of opioids prescribed also quadrupled.1 The increase in prescribing occurred in the context of a greater emphasis on treating pain following efforts by the American Pain Society, the Veterans Health Administration, The Joint Commission, and others to increase recognition and management of pain, as well as advocacy by pain societies urging physicians to use opioids more readily for patients with chronic noncancer pain.

Even though it is well known that prescription opioid use can lead to addiction or overdose, some opioid manufacturers and pain specialists suggest that few patients are susceptible to these risks.2- 3 To distinguish low-risk from high-risk patients, use of screening tools, including the Screener and Opioid Assessment for Patients with Pain, has been advocated.4 Medication guides include statements such as “the chance [of abuse or addiction] is higher if you are, or have been, addicted to or abused other medicines, street drugs, or alcohol, or if you have a history of mental problems.”5 While there is likely to be a gradient of risk across patients, this statement may reassure clinicians that people with opioid addiction are different from most patients for whom they provide care.

However, opioid dependence is much more common than previously believed and has been estimated to affect more than one-third of patients with chronic pain.6 No screening tool has sufficiently high sensitivity to rule out problems with opioids. Reported sensitivities of these tests for observed “aberrant drug-related behavior” (eg, dose escalation outside the treatment plan or forging prescriptions)4 among patients with chronic pain are generally within a range between 70% and 90%,4 which means that they miss 10% to 30% of patients at high risk of misuse or addiction.

In addition, some industry-sponsored educational brochures suggest that physicians should ignore signs of opioid dependence in low-risk patients.7 For instance, some patients might not be considered at high risk of misuse even though they may use more opioids than prescribed (one definition of misuse). Some authors have stated that behaviors such as taking more opioids than prescribed may represent pseudoaddiction,7 a concept introduced in a case report in 19898 as “abnormal behavior developing as a direct consequence of inadequate pain management.”8 However, this concept remains untested, without scientific studies validating diagnostic criteria or describing long-term clinical outcomes. Nonetheless, some pain societies have promoted this concept9 and suggest that some patients demonstrating behaviors typical of opioid addiction may actually require higher doses.9

Rather than representing iatrogenic undertreatment of pain, however, behaviors described as pseudoaddiction may represent predictable responses to opioid exposure. Long-term opioid use typically results in tolerance. A standard clinical solution is to increase opioid dose. However, contrary to the view that there is no maximum safe dose if opioids are increased gradually over time, death from opioid overdose becomes more likely at higher doses.

The most important risk factor for opioid analgesic–associated dependence or overdose is not a feature of any individual patient but instead simply involves receiving a prescription for opioids. For example, newly prescribed opioids after short-stay surgery are associated with a 44% increase in risk of becoming a long-term opioid user within 1 year.10

Another potential complication of screening for risk of opioid abuse is that identifying patients who should not receive opioids can stigmatize them, leading to consequences that do not help them. Patients who are questioned about substance use and then excluded from an expected treatment may feel embarrassed or abandoned. The decision to address a patient's pain should not depend on substance use history. Screening should be used primarily to identify and offer treatment to patients with opioid addiction.

Before prescribing opioids, a more useful and important question than a patient's likelihood of dependence is whether benefits of opioids in relieving pain are likely to outweigh the risks of the drugs. For pain control at the end of life, the answer to this question is often yes. If the indication for opioids is chronic noncancer pain, the answer to this question will be no much more often than many physicians may realize. Despite widely held views about the efficacy of opioids for pain control, systematic reviews have not found sufficient evidence that long-term opioid use controls noncancer pain more effectively than other treatments.

Physicians have a professional and ethical responsibility to understand the expected benefits and risks of medications and to balance these appropriately. When benefits of opioids are likely to outweigh risks, such as in severe acute pain unlikely to respond to other therapies, it is appropriate to use opioids, prescribing the lowest effective dose and with a duration limited to the likely duration of the acute pain. However, when risks outweigh benefits, as will often be the case for chronic pain, opioid use should be avoided in favor of other treatments.

Some physicians may think that only a small fraction of their patients are put at risk by taking high doses of opioids. However, the risk of opioids stems primarily from these drugs, not from patients. Low-risk patients given large enough doses will have a high risk of overdose. Patients given moderate doses for prolonged periods will have a high risk of opioid dependence. While a patient's estimated individual risk should be considered, physicians should pay close attention to the drug dose and duration. All patients exposed to opioids would benefit from judicious prescribing and close follow-up.

REFERENCES
1 Centers for Disease Control and Prevention. Primary care and public health initiative: balancing pain management and prescription opioid abuse: educational module. http://www.cdc.gov/primarycare/materials/opoidabuse/. Published October 24, 2012. Accessed May 6, 2013

2 Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health. 2009;99(2):221-227

3 The use of opioids for the treatment of chronic pain: a consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain. 1997;13(1):6-8

4Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. Pain Physician. 2012;15(3):(suppl) ES67-ES92

5 Purdue Pharma LP. Medication guide: OxyContin tablets. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022272s000remsOxycontin.pdf. Published March 22, 2010. Accessed May 3, 2013

6 Boscarino JA, Rukstalis MR, Hoffman SN, et al. Prevalence of prescription opioid-use disorder among chronic pain patients: comparison of the DSM-5 vs. DSM-4 diagnostic criteria. J Addict Dis. 2011;30(3):185-194


7 Stanos SP, Mahajan G. Appropriate Use of Opioids in Chronic Pain: Caring for Patients and Reducing Risks. [CME activity]. Englewood, CO: Postgraduate Institute for Medicine; 2012

8 Weissman DE, Haddox JD. Opioid pseudoaddiction—an iatrogenic syndrome. Pain. 1989;36(3):363-366
PubMed | Link to Article

9 American Academy of Pain Medicine, the American Pain Society and the American Society of Addiction Medicine. Definitions related to the use of opioids for the treatment of pain. WMJ. 2001;100(5):28-29 PubMed

10 Alam A, Gomes T, Zheng H, Mamdani MM, Juurlink DN, Bell CM. Long-term analgesic use after low-risk surgery: a retrospective cohort study. Arch Intern Med. 2012;172(5):425-430
 
http://well.blogs.nytimes.com/2013/05/13/hard-cases-the-traps-of-treating-pain/

Hard Cases: The traps of treating pain.

I hadn’t seen Larry in a dozen years when he reappeared in my office a few months ago, grinning. We were both grinning. I always liked Larry, even though he was a bit of a hustler, a little erratic in his appointments, a persistent dabbler in a variety of illegal substances. But he was always careful to avoid the hard stuff; he said he had a bad problem as a teenager and was going to stay out of trouble.

It was to stay out of trouble that he left town all those years ago, and now he was back, grayer and thinner but still smiling. Then he pulled out a list of the medications he needed, and we both stopped smiling.

According to Larry’s list, he was now taking giant quantities of one of the most addictive painkillers around, an immensely popular black-market drug most doctors automatically avoid prescribing except under the most exceptional circumstances.

“I got a bad back now, Doc,” Larry said.

Doctors hate pain. Let me count the ways. We hate it because we are (mostly) kindhearted and hate to see people suffer. We hate it because it is invisible, cannot be measured or monitored, and varies wildly and unpredictably from person to person. We hate it because it can drag us closer to the perilous zones of illegal practice than any other complaint.

And we hate it most of all because unless we specifically seek out training in how to manage pain, we get virtually none at all, and wind up flying over all kinds of scary territory absolutely solo, without a map or a net.

The events of the last few decades haven’t helped much. First came a consumer-driven “pain power” movement — justified, for the most part — pointing out that pain was wildly undertreated by most doctors. And then, more recently, came the new statistics on the widespread abuse of prescription narcotics, which now saturate street corner markets everywhere and cause more overdose fatalities than heroin and cocaine combined.

In other words, we are now cautioned in the strongest possible terms against giving too little medication and too much, being too free and too parsimonious, underprescribing to the right people and overprescribing to the wrong. Most official guidelines and policy statements, even fuller than usual of vacuous general principles, aren’t of much help in figuring how to do any of this.

One of the most accurate, articulate and heartfelt reflections on the situation was written a few years ago in Archives of Internal Medicine by Dr. Mitchell Katz, who now directs the Los Angeles County health department. Dr. Katz described his slow disillusionment with the standard approach to pain control, which involves escalating from nonnarcotic to narcotic medication, then prescribing as much as needed to eradicate the pain, while deploying measures like written contracts, pill counts and urine tests to make sure the patient is taking it all as prescribed.

It is awfully hard to take that road without turning into the patient’s parole officer. And so, Dr. Katz suggested, how about a regulatory body establishing a reasonable cap for narcotic dosing, at least for people without malignant diseases who are likely to be taking them long-term? :thumbup:Also, how about formally acknowledging that sometimes pain cannot be entirely eradicated? “Leaning how to cope with pain can be more empowering for patients than trying to find a pill to completely eliminate it,” he wrote.

Clearly Larry’s last doctor wasn’t buying into these sentiments, given the quantities of medication Larry was asking for — assuming there actually was a previous doctor in Larry’s life. All I had for evidence was a list, in Larry’s handwriting. The pills themselves, the bottles? “They got stolen off me on the bus here,” Larry said.

When was that?

“Last month,” Larry said.

Ultimately, all careful nomograms fall aside in the face of the particular patient. I was lucky enough to know Larry pretty well, although in some ways that only made things more difficult. I knew he was a decent and intelligent guy, with a pretty sophisticated understanding of his own problems and a hard time keeping straight. I also knew he was clearly walking with the careful “don’t touch me” gait of someone with a really bad back.

And Larry, of course, knew me well, too — well enough not to be surprised when I sent him off with a sheaf of referrals to evaluate his back, a weaker, nonnarcotic pain reliever, and not a single one of the requested pills. He just smiled and said, “I knew you wouldn’t give them to me.”

These decisions are always harder than hard; you have nothing but instinct and experience to guide you, and you never know if you’ve done the right thing. I think about Larry periodically, but I haven’t seen him since.
 
Effect of a course-based intervention and effect of medical regulation on physicians’ opioid prescribing
Meldon Kahan, MD MHSc CCFP FRCPC⇑
Associate Professor and Research Scholar in the Department of Family and Community Medicine at the University of Toronto (U of T) in Ontario and Medical Director of the Substance Use Service at Women’s College Hospital in Toronto.
Correspondence: Dr Meldon Kahan, Complex Care Clinic, Women’s College Hospital, 6th Floor, 76 Grenville St, Toronto, ON M5S 1B2; telephone 416 323-7559; e-mail [email protected]
Tara Gomes, MHSc
Scientist at the Institute for Clinical Evaluative Sciences in Toronto.
David N. Juurlink, MD PhD FRCPC
Associate Professor in the Department of Medicine, the Department of Paediatrics, and the Department of Health Policy, Management and Evaluation at U of T.
Michael Manno, MSc
An analyst at the Institute for Clinical Evaluative Sciences.
Lynn Wilson, MD CCFP FCFP
Associate Professor and Department Chair in the Department of Family and Community Medicine at U of T.
Angela Mailis-Gagnon, MD MSc FRCPC
Director of the Comprehensive Pain Program at the Toronto Western Hospital.
Anita Srivastava, MD MSc CCFP
Assistant Professor and Research Scholar in the Department of Family and Community Medicine at U of T.
Rhoda Reardon, Dip(P&OT)
Manager of the Research and Evaluation Department at the College of Physicians and Surgeons of Ontario in Toronto.
Irfan A. Dhalla, MD MSc FRCPC
Scientist and a staff physician in the Keenan Research Centre of the Li Ka Shing Knowledge Institute at St Michael’s Hospital in Toronto.
Muhammad M. Mamdani, PharmD MA MPH
+ Author Affiliations

Director of the Applied Health Research Centre and Scientist in the Keenan Research Centre of the Li Ka Shing Knowledge Institute at St Michael’s Hospital.
Abstract

Objective To examine the effects of an intensive 2-day course on physicians’ prescribing of opioids.

Design Population-based retrospective observational study.

Setting College of Physicians and Surgeons of Ontario (CPSO) in Toronto.

Participants Ontario physicians who took the course between April 1, 2000, and May 30, 2008.

Intervention A 2-day opioid-prescribing course with a maximum of 12 physician participants. Educational methods included didactic presentations, case discussions, and standardized patients. A detailed syllabus and office materials were provided.

Main outcome measures Participants were matched with control physicians using specific variables. The primary outcome was the rate of opioid prescribing, expressed as milligrams of morphine equivalent per quarter.

Results One hundred thirty-eight course participants (120 family physicians, 15 specialists, and 3 physicians whose status was uncertain) were eligible for analysis. Of these, 68.1% were self-referred and 31.9% were referred by the CPSO. Overall, among physicians referred by the CPSO, the rate of opioid prescribing decreased dramatically in the year before course participation compared with matched control physicians. The course had no added effect on the rate of physicians’ opioid prescribing in the subsequent 2 years. There was no statistically significant effect on the rate of opioid prescribing observed among the self-referred physicians. Among 15 of the self-referred physicians who, owing to the high quantities of opioids they prescribed, were not matched with control physicians, the rate of opioid prescribing decreased by 43.9% in the year following course completion.

Conclusion Physicians markedly reduced the quantities of opioids they prescribed after medical regulators referred them to an opioid-prescribing course. The course itself did not lead to significant additional reductions; however, a subgroup of physicians who prescribed high quantities of opioids might have responded to what was taught in the course.

Copyright© the College of Family Physicians of Canada
 
http://www.tillamookheadlightherald.com/news/article_73afbd02-0571-11e1-b703-001cc4c002e0.html

Proof of Pain
Posted: Wednesday, November 2, 2011 9:39 am | Updated: 9:47 am, Wed Nov 2, 2011.
By Samantha Swindler

WHEELER - A prominent north county doctor's efforts to ease his patients' suffering have gained him statewide recognition as a "Pioneer in Pain."
But he's also drawn the attention of local law enforcement.
"It's incredibly controversial," said Dr. Harry Rinehart, medical director of the Rinehart Clinic. "There are people who hate me because I take care of people with chronic pain and addictions."
Rinehart feels we have "undermedicated" pain patients. But Tillamook County District Attorney William Porter fears too many prescription narcotics end up with drug addicts.
Porter said he's filed several complaints against Rinehart to the Board of Medicine.
All of them have been dismissed.
"The aim here is not to prevent anyone who is legitimately receiving treatment," Porter said. "But there's also a significant question of at what point do you look at non-narcotic alternatives?"
Law enforcement deals with the addicts and abusers of narcotic prescriptions. Rinehart said he sees a different side of the drug - people in pain and unable to get help from other doctors.
"People with chronic pain, if they're treated appropriately so they're not overmedicated, and they're not undermedicated, so they can be more functional, are some of the most appreciative patients, and they're really great, great people to work with," Rinehart said.
In April, Rinehart began prescribing narcotics in group sessions rather than during individual appointments. Once every three months, patients must attend a group pain management meeting to have their prescriptions refilled.
He's believed to be the only doctor in the state with such a practice.
"Groups for other conditions have been shown to be really pretty dramatic as far as people doing better with whatever their condition is," Rinehart said. "And because people form bonds, they have camaraderie, they help each other."
Rinehart said the groups allow him to spend more time teaching broader concepts about coping with chronic pain - exercises, dietary changes and understanding why the body registers pain in a certain way.
He has more than 300 pain patients.
"Most people are concerned about the group sessions the first time around, but we have people who just love groups. They think it's the best thing we've done."
THE GROUP MEETING
On a Friday morning, 11 people gather in a room at the Nehalem Bay Health District for a chronic pain management meeting. Rinehart opens the meeting by requiring all attendees to show him pictures of their home safes with their pills inside, or otherwise to bring in the lock box in which they hold their medications.
Rinehart has always required his patients to lock up their narcotic prescriptions. But one man was not happy about this new requirement of photographic evidence. He wanted to talk to his attorney and said "where it (the medication) is at, it's private. It's taking it too far."
But Rinehart was adamant. He lifted his wrist, displaying a silicone wristband with "Megpie" written across it.
"That's the bracelet for the little 15-year-old who died because she got methadone," he said. "Now that's ‘carried away.' So when it comes to some teenager's life or your concern, her life takes precedence...
"These drugs are absolutely lethal, and we have a responsibly in the community to keep them safe."
Megan Price died from an overdose after getting access to her step-mother's prescribed methadone. The family is now selling memorial wristbands for $4 each. The money will go toward making an anti-drug video to be shown to area students.
Rinehart makes all his pain patients sign an agreement - they will lock up their drugs, they won't share them and they won't see another doctor for additional prescriptions.
There's no doubt that the narcotics being prescribed are powerful. So are the patients' stories. Every one of them in the group session says "Doc" - as they affectionately call Dr. Rinehart - has changed their lives.
"I had gone to many, many, many doctors and the last doctor told me that 98 percent of people in U.S. have back pain," one patient said. "You felt they were blowing you off. I have more medical history of being blown off than anything else."
Many doctors opt not to treat chronic pain patients because of the added federal scrutiny and potential for narcotic abuse.
"It's a stigma," said one young man who comes to see Rinehart from Astoria. "I've been to a few doctors and all they want to do is surgery, it's your only answer. And with this doctor, there's always something new to try. Most of the other doctors said ‘you're either faking it or you're a junkie.'"
The man from Astoria just turned 30. He played football and threw discus in high school and had back surgery at age 17. Rinehart has prescribed him methadone. "I take them on the hour," he said. "I just get a nice pile in my system and I can deal. It's not like I'm high.. it takes that pain from a level 5 to a 2 or 3 so where if there's something that's worth doing, I'll get up and go do it."
He also takes lithium, a mood stabilizing drug; morphine at night to sleep; and has a medical marijuana card.
He says Rinehart's treatments have changed his life for the better.
Another patient - a middle-aged, overweight man who said he's had four back surgeries - takes six oxycodone pills daily, but has "breakthrough" pain every day. "Breakthrough" pain comes on suddenly, and is above and beyond the regular level of chronic pain.
"It would be perfectly reasonable to give you another two oxycodone to take if you're going to go mow the lawn," Rinehart told him.
In street value, these drugs would be worth plenty - a single 80 milligram oxycodone pill sells illegally for about $80.
"A lot of people who aren't involved in chronic pain are surprised by how much they are taking," Rinehart said of his patients' doses. In the state of Washington, he said 120 milligrams a day of morphine is the maximum allowed for those on workers compensation, "and Oregon is beginning to follow suit. As many of you know, that wouldn't touch what you're doing," he told the group.
The meeting isn't just about narcotics. Group members talk about other ways to ease their pain. One woman shared how eating a "clean diet" has helped. Fewer processed foods and sugars seemed to have positive effects on pain, she said.
During the meeting, Rinehart also encourages his patients to put a few pills away in case of winter storms, which might prevent them from reaching the pharmacist.
"If you have a really good day, you have to put a pill away," he told them. "That's perfectly, absolutely reasonable and if you have some left over, we don't say that's underutilized, we would like you to have a few so you don't go into withdrawal."
At the end of the meeting, before he starts to sign off on all the prescriptions for the next three months, Rinehart asks the group, "Anybody have side-effects? Constipation? Sexual disfunction?"
No one says a word.
‘OPIATE PHOBIA'
On Oct. 1, Rinehart was awarded the annual Pioneer in Pain award by the Oregon Pain Society. While the group pain sessions weren't the reason he was awarded the honor, Jennifer Wagner, executive director of the Western Pain Society and the Pain Society of Oregon, said it is another example of Rinehart's dedication to his patients.
"It's a pretty new thing that he's starting to do... I haven't heard of any practice doing that," she said. "I think it shows Harry is innovating in a rural community where there are not a lot of other providers. He is constantly thinking of ways to treat patients."
Rinehart received the award for his long history of treating pain. He began his practice in Prineville in 1978 after he got out of the Army. In 1992, he returned to Wheeler, to take over the medial practice begun by his grandparents in 1913. Today, the Rinehart Clinic is a 501c3 non-profit clinic that treats patients regardless of their ability to pay.
From the beginning of his practice in Prineville, pain management has been an important part of Rinehart's family practice.
"I hadn't been in town two years when I was investigated by the Board of Medical Examiners for prescribing about four 5-milligram Percocets a day to an elderly woman in a nursing home with arthritis of her knees," Rinehart said.
"The investigator was here in town three days, went through all the pharmacy records, and he met with me and he said that was the problem, I was prescribing four Percocet a day to this woman who was nearing the end of her life in a nursing home, which today it's just laughable because that is such a small dose."
Wagner said Rinehart has been investigated by the Oregon Medical Board more than a dozen times, but has never had any disciplinary action taken against him. She sees it as an example of Rinehart's commitment to patient care, regardless of the obstacles.
"The Institute of Medicine just released a report," Wagner said. "They estimate that 116 million Americans have chronic pain - that's more than cancer, diabetes and heart disease combined. In my opinion we have two public health crises happening - the hospitalization and deaths related to opiate overdose and abuse. At the same time, we have a public health crisis with the under-treatment to pain. And one is the response to the other, and we need to be careful about it."
Part of the problem is the subjective nature of pain. There's no test to determine a person's pain level. And the same injury could result in very different feelings of pain in two different individuals.
"We could have the same injury and I could have a pain level of a 4 and you could have a 2, and both are true and valid, but it's different based on us," Wagner said.
Treating chronic pain then becomes particularly problematic, because the most effective drugs for that treatment are addictive and can be diverted to illegal street use.
"At this point in time, one in five adult Americans have some chronic pain," Rinehart said. "Not every one of them needs a pain pill. But many of them are able to function far better if they have pain control. And so throughout the 1980s and 1990s there was a realization that people were being undermedicated. And there were a lot of educational programs about use of opioids for pain."
But, he says, the "pendulum swung" in the other direction as the problem of abuse became more prevalent.
"People are afraid of opiates," Rinehart said, "and this country has not had a rational approach to the treatment of pain or the issue of pain since the get-go. In the 1960s the DEA was scheduling drugs - so when around 30 percent of the population is having trouble with alcohol, 5 percent with opioids, what did they schedule? Opioids. They said this is the bug-a-boo. But we know that's not the case, it's alcohol..."
Rinehart is also one of 19 volunteer members of the Oregon Pain Management Commission, a state organization that seeks to "improve pain management... through education, development of pain management recommendations, development of a multi-discipline pain management practice program for providers, research, policy analysis and model projects."
"Inadequate pain relief is a serious public health problem in the United States," reads the 2006 statement on Pain Management by the Oregon Pain Management Commission. "Estimates of Americans suffering from chronic pain range from 20-30 percent of the population... Pain continues to be under-treated. This causes unnecessary suffering and reduced function and quality of life in people with pain as well as increased healthcare utilization and lost workforce productivity."
DEPENDENCE & ADDICTION
One of the biggest misconceptions about chronic pain is the difference between dependence and addiction.
A diabetic who abruptly stopped taking his insulin would go into serious withdrawals, Wagner said. That patient is dependent on the insulin drug. And yet, a pain patient dependent on opioids faces far different scrutiny.
The American Society of Addiction Medicine defines addiction by the characteristics displayed: "impaired control over drug use, compulsive use, continued use despite harm, and craving."
Properly medicated patients may be dependent on their drugs - simply meaning they may face withdrawal symptoms if abruptly taken off the drug. Those who are addicted have a continued craving for the drug; they may take it to the point that they are unable to work or function normally.
Additionally, Rinehart believes an over-criminalization of prescription pills has led some patients to become "pseudo-addicts." They display some traits of addicts - such as forging prescriptions or doctor shopping - only because doctors aren't adequately treating the pain they have.
Rinehart doesn't treat addicts within the same group sessions as his chronic pain patients, nor with the same drugs.
He is one of the only doctors on the coast currently allowed to prescribe Suboxone.
The brand Suboxone, which contains the drug buprenorphine, was approved by the Food & Drug Administration in 2002 for use in opioid addiction treatment. It's also a Schedule III narcotic, making its illegal sale a felony.
Buprenorphine is a "opioid partial agonist," which means it doesn't have the maximum euphoric effects of drugs such as heroin, oxycodone or methadone. At low doses for addicts, it curbs withdrawal symptoms without giving a high. And unlike methadone, buprenorphine has a "ceiling effect" of about four pills, so higher dosages have no effect on a user. Supporters say the chemical properties of the drug make it less likely to be abused than other opioids.
Still, police warn that Suboxone is rapidly becoming a street drug among addicts.
"Suboxone, if used properly, can be a great tool for helping an opiate addict," said Detective Paul Fournier with the Tillamook Sheriff's Office. "The problem is that the diversion of Suboxone is similar to the diversion of the opiate in the first place. We find them selling, trading Suboxone. It becomes a commodity in the drug trade. A user who has no intention of getting clean will stockpile them, and when heroin becomes unavailable they take it to not get sick."
As an officer, Fournier sees a growing number of pain pill addicts. And it's not just a problem in Tillamook County.
In the past few years, Americans' trips to the emergency room because of prescription painkillers have more than doubled - from 144,644 in 2004 to 305,885 in 2008.
"The majority of opiate abuse in this county is of prescribed medication," Fournier said. "We are seeing people that may not be smoking it, may not be shooting it up, but they are so addicted to their pain killers that ... they are a shell of the person they were."
THE JAIL'S POLICY
Even with a valid prescription, if you're arrested and end up in the Tillamook County Jail, you'll quickly be weaned from your narcotics.
That's because at the jail, powerful prescription narcotics can be a problem.
"I'd say probably between 40-60 percent of the patients (at the jail) who come in are claiming to be using some kind of a prescription narcotic," said Dr. John Zimmerman, the medical director of the Tillamook County Health Department.
Zimmerman is contracted to provide medical services for the county inmate population. He's taken a strong stand to cut the high use of prescription narcotics among the inmates.
"When inmates come into the jail, they may or may not be on narcotic prescriptions. A lot of them claim to be, but they're really not," Zimmerman said. "With the problems that exist among the inmate population anyway - drug abuse and all those kinds of things, as well as alcohol abuse - (opioid use) is not a situation that is amenable to the jail population... The policy at the jail has been for quite a while to wean these people off their narcotics in a safe and reasonable way, using medication to treat their side effects."
Inmates are treated with over the counter medications - ibuprofen, Tylenol and aspirin. Patients will go through withdrawals for the first few days, he said, but opioid withdrawal is not life-threatening.
"Many times... when I do an evaluation of what's going on with them, I find an entirely inappropriate prescription in the first place, and that their medical condition doesn't warrant chronic narcotics anyway," Zimmerman said.
He added that the jail staff's medical care focus - which is paid for with public monies used to operate the jail - is on acute or life-threatening problems.
"For the most part, medications that are administered on a daily basis at the jail are for chronic medical conditions that could cause serious situations if they're not treated," Zimmerman said. "Chronic pain does not fall into that category."
But Wagner has serious concerns about the jail's policy.
"If a chronic pain patient has chronic pain, you can't just remove them from their pain medication and think they're fine," she said. "That person is indefinitely suffering... There's no reason to take them off their medication. It should be the same as other medication that a patient has."
Wagner and the Oregon Pain Society have advocated for better access to pain management care for patients - including access to opioid narcotics. She believes doctors are under-medicating pain patients because of the stigmas of prescribing narcotics.
But Zimmerman disagrees. Asked if doctors in general are overprescribing narcotics, Zimmerman, who also has a family practice, said, "I would say yes, in a lot of respects.
"I think the biggest problem has to do with the chronic prescription of narcotics," he said. "It's hard to argue with somebody who falls off their porch and has a gash in their leg and a huge bruise... It's when people are prescribed narcotics on a chronic basis without certain guidelines being observed before this stuff is prescribed."
Drug abuse or over-use appears to be growing. In the past few years, Americans' trips to the emergency room because of prescription overdose have more than doubled - from 144,644 in 2004 to 305,885 in 2008.
State-wide, 53 percent of drug overdoses are associated with prescription opioids.
PREVENTING DIVERSION
Local drug-related crime statistics are kept by class of drug without distinguishing between legal and illegal drugs, so the district attorney's office can't provide a breakdown of exactly how many criminal cases in the area involve prescribed narcotics.
But Tillamook District Attorney William Porter said, "I can tell you that of the non-marijuana unlawful use drugs, prescription drugs are sneaking up on probably 50 percent of the possession case load."
Most of the cases that end up before the district attorney's office are people stopped for an unrelated crime who are found under the influence or illegally in possession of a narcotic.
"The majority of opiate abuse in this county is of prescribed medication," said Det. Fournier.
Fournier had no comment on the practices of any specific doctors in Tillamook County. "I would say that I still believe that opiates are prescribed for longer period of times and at a higher volume than are therapeutically necessary," he said. "Doctors and pharmacists should be aware that these things should be treated like loaded weapons."
MONITORING PRECRIPTION DRUGS
The state has taken some steps to prevent "doctor shopping"- patients seeking prescriptions from multiple doctors and filling them at multiple pharmacies.
The extra pills can be sold on the street, or abused for a high by the patient.
Up until recently, no state system tracked the dispensation of these narcotics. But the Oregon Prescription Drug Monitoring Program went online Sept. 1. The program requires pharmacies to electronically report prescription data for Schedule II, III and IV controlled substances. That includes opioids.
The program is in its infancy and still uploading data. But law enforcement is optimistic that it may make it harder for patients to abuse prescription drugs.
Additionally, Fournier hopes healthcare professionals realize the affects of prescription drug abuse. Pain pill addicts, he said, live in a fog and become "a shell of the person they were.
"Maybe (doctors) are not seeing what we're seeing - the overdosing or the grandchildren and children of these patients who are using it," he said. "I don't think there's enough care being given with these prescriptions."

http://www.painsociety.com/conference/annual/pioneeraward.php

http://www.lanecounty.org/departmen...egon_hidta_threat_assessment_final_062112.pdf

Controlled Prescription Drug Use
The threat posed by misuse of controlled prescription drugs (CPDs)
has grown dramatically in in the United States in recent years.53 The most recent federal data shows that non-medical use of
prescription drugs grew nearly sixfold nationally between 1992 and 2009, with opioid pain relievers
responsible for more drug-related deaths than heroin and cocaine combined.54 In addition, hospital
emergency department visits involving nonmedical use of prescription pain relievers nearly doubled
between 2004 and 2009 in the United States, the latest data available.
55
The misuse of prescription drugs has resulted in an emerging market in Oregon (Table 1). Over
70 percent of Oregon law enforcement officers surveyed in early 2012 reported a high level of illicit
prescription drugs available in their area, with one agency in Tillamook County reporting CPDs as the
area's greatest drug threat (Figure 1, page 5). Most officers surveyed (76%) indicated a high level of
narcotics, such as oxycodone (e.g., Oxycontin) and hydrocodone (e.g., Vicodin), were diverted in their
region, with slightly fewer reporting high levels of depressants (11%) and stimulants (6%).
56 According to a 2011 federal study, Oregon's rate of non-medical opioid use is second highest in the
nation and fourth in the quantity of kilograms sold (per 10,000 residents) in
2008.57 Treatment admissions for CPDs increased
more than threefold in Oregon in the last nine years
(CY 03-CY11, Figure 9, page 14), 58 with the reported
number of unintentional deaths (most due to
prescription drug poisoning) rising faster than any
other type of injury.59 Analysis of admission data for
the HIDTA region follows statewide trends with a
more than threefold rise in related admissions from
2003 through 2011 (Figure 4, page 7).60
 
Last edited:
Top